PHILADELPHIA, Nov. 4 /PRNewswire/ -- Acuity Pharmaceuticals, a product-focused ophthalmic pharmaceutical company, today announced that it will present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference at the New York Palace Hotel in New York City on Tuesday, November 8, 2005 at 4:55pm EST in the Adams Room.
Acuity CEO and president Dr. Dale Pfost will provide an overview of the company and discuss recent corporate developments, including Acuity's initiation of phase ll clinical trials for its lead compound Cand5 in age-related macular degeneration. Cand5 is the first therapy based on the exciting new gene silencing technology of RNA interference (RNAi) to enter human trials and now to progress to phase ll studies. Its unique mechanism of action has the potential to deliver efficacy, safety and administration benefits compared to other approaches.
Founded in 2002, Acuity Pharmaceuiticals is a product-focused ophthalmic pharmaceutical company applying its proprietary technology to the treatment and prevention of ophthalmic diseases, focusing initially on leveraging its strong technology and intellectual property portfolio in the field of RNA interference (RNAi). Acuity is developing treatments for age-related macular degeneration (AMD) and diabetic retinopathy (DR), two of the leading causes of adult vision loss in the developed world. Its lead clinical compound Cand5, a small-interfering RNA (siRNA) therapeutic currently in Phase ll trials, shuts down vascular endothelial growth factor (VEGF), which has been shown to be the central stimulus in the development of AMD and DR. In late 2004, Cand5 became the first-ever RNAi therapy to enter human trials. Its novel siRNA mechanism of action is expected to give Cand5 efficacy, safety and administration advantages over other therapies. For more information,visit www.acuitypharma.com
Acuity Pharmaceuticals GendeLLindheim BioCom Partners
Todd Wallach Barbara Lindheim
215 966-6181 212 918-4650
CONTACT: Todd Wallach of Acuity Pharmaceuticals, +1-215-966-6181, orBarbara Lindheim of GendeLLindheim BioCom Partners, +1-212-918-4650